Sanofi CEO Viehbacher ousted unanimously by its board

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Sanofi CEO Viehbacher ousted unanimously by its board

After a few tense days, with talk of a potential ouster swirling, Sanofi's ($SNY) board "decided unanimously to remove Christopher A. Viehbacher as Chief Executive Officer of Sanofi," according to a brief statement. As Sanofi's first non-French CEO, Viehbacher wasn't wedded to its French operations--in fact, he openly criticized domestic R&D--and that ruffled feathers with labor unions, politicians and, obviously, the Sanofi board. But Viehbacher's choice to plow resources into a research hub in Cambridge, MA, while cutting back in France, along with moves to build up operations and sales internationally, were popular with investors. Read the full story from FiercePharma

Sanofi
Chris Viehbacher is out from the CEO position.


Synthetic Genomics
Oliver Fetzer joined as the company's new CEO.

Biotech

> Cerulean CEO Oliver Fetzer stepped down from his CEO position there to take the helm at J. Craig Venter-founded Synthetic Genomics. Release | Release

> VECT-HORUS has appointed Jamal Temsamani as director of drug development and corporate. Release

> ABIVAX has appointed Dr. Karl Birthistle as its vice president of global regulatory affairs and Daniel Kenny as its chief commercial officer and vice president of business development. Release

> H. Stewart Parker has joined Impel NeuroPharma's board of directors. Release

> Affinivax has appointed Frances Heller to the company's board of directors. Release

> AusBiotech has appointed Julie Phillips as chairman, and Serina Cucuzza, Barry Thomas and Serg Duchini to its board of directors. Release

> Nabsys appointed Anthony Shuber to be its chief scientific officer. Release

> Attila Hajdu joined Sirona Biochem as its chief business development officer. Release

> Epizyme ($EPZM) Chief Medical Officer Dr. Eric Hedrick stepped down from his post. Release

> Clarus Ventures appointed Dr. Barry Gertz to venture partner and Dr. Ari Brettman as an associate based in the firm's Cambridge, MA, office. Release

> Raze Therapeutics named Mikel Moyer the company's vice president of molecular discovery. Release

> Regenxbio brought on Dr. Stephen Yoo as its chief medical officer. Release

> Dr. Jennifer Low and Dr. Lori Kunkel joined Loxo Oncology ($LOXO) as its chief medical officer and a member of its board of directors, respectively. Release

> Robin Stracey, currently a member of Cesca Therapeutics ($KOOL)'s board of directors, will serve as interim CEO. The company is searching for a replacement for former CEO Matthew Plavan, who will serve as an adviser during the process. Release

> Aileron Therapeutics has added Dr. Manuel Aivado as chief medical officer and Donna Jarlenski as vice president of clinical operations and program management. Release

> Alnylam Pharmaceuticals ($ALNY) has appointed Dr. Pushkal Garg to senior vice president of clinical development. Release

Pharma

> Ciclofilin Pharmaceuticals has appointed Michael Kamdar to its board of directors. Release

> Ciclofilin also brought on Stephen Keane as senior vice president of corporate development. Release

> Mapi Pharma has appointed Charles Makin as vice president of health economics and outcomes research and strategic market access. Release

> Catalyst Pharmaceutical Partners ($CPRX) appointed David Caponera as its vice president of patient advocacy and reimbursement. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.